EVO101

Evommune abandons EVO101, a topical IRAK4 inhibitor, for atopic dermatitis

Evommune abandons EVO101, a topical IRAK4 inhibitor, for atopic dermatitis

Anika Sharma

Evommune, a California-based biotech company, has made the strategic decision to discontinue its sole clinical-stage asset, EVO101, following a thorough ...